-
MannKind: Advised by Cooley LLP, with partners Rowook Park and Mischi a Marca leading the team.
-
ScPharmaceuticals: Advised by Latham & Watkins LLP, though full counsel details were not available Monday.
If approved, the deal will not only diversify MannKind’s pipeline but also position the company as a rising force in cardiorenal innovation—staking a $360 million claim on the future of patient-focused biopharmaceutical care.
